Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 85,906 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Mental Health Wellness 1
Interventions: Peer Mentors; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: Chronic Plaque Psoriasis, Psoriasis
Interventions: M923, Humira; Biological
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 24
States / cities: Beverly Hills, California • Encino, California • La Mesa, California + 20 more

Conditions: Binge Eating Disorder
Interventions: Sodium Oxybate; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Drug · Diagnostic Test · Genetic
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide, Ramipril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Conyers, Georgia + 3 more

Conditions: Advanced Solid Tumor
Interventions: Pimasertib, Temsirolimus; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Los Angeles, California • Rockland, Massachusetts • Houston, Texas

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: E/C/F/TAF, E/C/F/TAF (Low Dose); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pneumococcal Disease
Interventions: Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15; Other · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 18
States / cities: Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more

Conditions: Carcinoma of the Head and Neck
Interventions: Taxotere, Oxaliplatin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Incipient Interproximal Caries
Interventions: 0.05% Sodium Fluoride with Self-Assembling Peptides; Drug
Lead sponsor: Tripler Army Medical Center; Federal
Eligibility: 18 Years to 74 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Schofield Barracks, Hawaii

Conditions: AMI
Interventions: Insulin Glargine (LANTUS), Insulin Glulisine (Apidra), Standard Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Triple Negative Breast Cancer
Interventions: ribociclib, Bicalutamide; Drug
Lead sponsor: Kari Wisinski; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 6
States / cities: Chicago, Illinois • Lansing, Michigan • New Brunswick, New Jersey + 3 more

Conditions: Skin Manifestations
Interventions: adapalene cream 0.1%, adapalene lotion 0.1%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Carrollton, Texas

Conditions: Healthy
Interventions: amikacin/fosfomycin; Drug
Lead sponsor: Cardeas Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Mood Disorders, Hypertension, Diabetes, Hypercholesterolemia
Interventions: Acceptance and Commitment Therapy plus Illness Management; Behavioral
Lead sponsor: Lilian N. Dindo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Urinary Tract Infection
Interventions: Nitrofurantoin, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ankle Sprain
Interventions: Esflurbiprofen Hydrogel Patch; Drug
Lead sponsor: Teikoku Seiyaku Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Back Pain, Sciatica
Interventions: Desipramine, Fluoxetine, Benztropine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab Prefilled Syringe, Rocatinlimab AI; Combination Product
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 22
States / cities: Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more

Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Interventions: Tradipitant, Placebo, Open Label Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 979 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 30 more

Conditions: Cystic Fibrosis
Interventions: N91115; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Adult T Cell Leukemia, Adult T Cell Lymphoma
Interventions: IMTOX-25; Drug
Lead sponsor: Amit Verma; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: The Bronx, New York

Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: bortezomib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Qoyangnuptu: Peer Mentor

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Sodium Oxybate in the Treatment of Binge Eating Disorder

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck

Can SAP P11-4 Affect The Appearance of Interproximal Cavities on an X-ray in a Military Population

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Ribociclib and Bicalutamide in AR+ TNBC

Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers

One-Day Acceptance and Commitment Training Intervention in Primary Care Patients

Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)

Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain

Effect of Antidepressants on Back Pain

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer